Dosage Guidelines for Foscarbidopa/Foscarbidopa for Injection

Foscarbidopa/foslevodopa for injection (foscarbidopa/foslevodopa) is a drug used to treat fluctuating motor symptoms in adults with advanced Parkinson's disease (PD). Foscarbidopa/Foscarbidopa is administered by continuous subcutaneous infusion to provide stable and sustained dopaminergic support to alleviate fluctuations in motor symptoms in patients with Parkinson's disease.

The initial dose and infusion rate should be individually adjusted by the physician based on the patient's specific conditions, such as weight, severity of illness, and tolerance. Typically, the physician will calculate the initial subcutaneous infusion rate based on the patient's previous oral equivalent dose of levodopa.

At the beginning of treatment, the doctor may gradually increase the infusion rate to achieve the best therapeutic effect. Dosage adjustments should be based on patient symptom improvement, adverse reactions, tolerability and other factors. The maximum recommended daily dose of foscarbidopa/foscarbidopa is 3,525mg of the phospho-levodopa component (equivalent to approximately 2,500mg of levodopa). Patients should avoid exceeding this maximum recommended dose to avoid increasing the risk of adverse effects.

If a patient develops a "shutdown" state (i.e., a sudden worsening of symptoms) during treatment, the doctor may give an additional loading dose to quickly relieve symptoms. The specific value of the loading dose should be calculated and administered by the doctor based on the patient's specific conditions.

Foscarbidopa/Foscarbidopa is for subcutaneous administration only, usually as a continuous infusion via a specialized infusion pump.

During treatment, patients should be regularly evaluated by their physician to monitor factors such as symptom improvement, adverse reactions, and tolerability. Your doctor may adjust the infusion rate and dose based on your evaluation.

Foscarbidopa/Foscarbidopa may cause a series of adverse reactions, such as injection site reactions, infection, hallucinations, and movement disorders. When patients experience adverse reactions, they should promptly inform the doctor so that the doctor can take corresponding measures.

Reference materials:https://www.vyalev.com/